Combination of micelles and liposomes as a promising drug delivery system: a review.
Composite carrier
Drug delivery
Liposome
Micelle
Nanoformulation
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
accepted:
18
05
2023
medline:
23
10
2023
pubmed:
6
6
2023
entrez:
6
6
2023
Statut:
ppublish
Résumé
Among various nanocarriers, liposomes, and micelles are relatively mature drug delivery systems with the advantages of prolonging drug half-life, reducing toxicity, and improving efficacy. However, both have problems, such as poor stability and insufficient targeting. To further exploit the excellent properties of micelles and liposomes and avoid their shortcomings, researchers have developed new drug delivery systems by combining the two and making use of their respective advantages to achieve the goals of increasing the drug loading capacity, multiple targeting, and multiple drug delivery. The results have demonstrated that this new combination approach is a very promising delivery platform. In this paper, we review the combination strategies, preparation methods, and applications of micelles and liposomes to introduce the research progress, advantages, and challenges of composite carriers.
Identifiants
pubmed: 37278964
doi: 10.1007/s13346-023-01368-x
pii: 10.1007/s13346-023-01368-x
doi:
Substances chimiques
Liposomes
0
Micelles
0
Drug Carriers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2767-2789Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Controlled Release Society.
Références
Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnol Rev. 2021;10:1941–77.
doi: 10.1515/ntrev-2021-0115
Mundekkad D, Cho WC. Nanoparticles in clinical translation for cancer therapy. Int J Mol Sci. 2022;23:1685.
pubmed: 35163607
pmcid: 8835852
doi: 10.3390/ijms23031685
Lôbo GCNB, Paiva KLR, Silva ALG, Simões MM, Radicchi MA, Báo SN. Nanocarriers used in drug delivery to enhance immune system in cancer therapy. Pharmaceutics. 2021;13:1167.
pubmed: 34452128
pmcid: 8399799
doi: 10.3390/pharmaceutics13081167
Ramos TI, Villacis-Aguirre CA, López-Aguilar KV, Santiago Padilla L, Altamirano C, Toledo JR, et al. The Hitchhiker’s guide to human therapeutic nanoparticle development. Pharmaceutics. 2022;14:247.
pubmed: 35213980
pmcid: 8879439
doi: 10.3390/pharmaceutics14020247
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomed. 2019;14:1937–52.
doi: 10.2147/IJN.S198353
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–99.
doi: 10.2147/IJN.S68861
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238–52.
pubmed: 5859039
doi: 10.1016/S0022-2836(65)80093-6
Li J, Sun C-K. In vitro analysis of microRNA-26a in chronic lymphocytic leukemia cells. Int J Mol Med. 2018;42:3364–70.
pubmed: 30320374
pmcid: 6202071
Liu D, Yang PS. Minocycline hydrochloride nanoliposomes inhibit the production of TNF-α in LPS-stimulated macrophages. Int J Nanomed. 2012;7:4769–75.
doi: 10.2147/IJN.S34036
Gregoriadis G, Leathwood PD, Ryman BE. Enzyme entrapment in liposomes. FEBS Lett. 1971;14:95–9.
pubmed: 11945728
doi: 10.1016/0014-5793(71)80109-6
Li M, Du C, Guo N, Teng Y, Meng X, Sun H, et al. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–53.
pubmed: 30640028
doi: 10.1016/j.ejmech.2019.01.007
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
pubmed: 23036225
doi: 10.1016/j.addr.2012.09.037
Khan AA, Allemailem KS, Almatroodi SA, Almatroudi A, Rahmani AH. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 2020;10:163.
pubmed: 32206497
pmcid: 7062946
doi: 10.1007/s13205-020-2144-3
Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115:10938–66.
pubmed: 26010257
doi: 10.1021/acs.chemrev.5b00046
Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantù L, et al. Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release. 2021;332:312–36.
pubmed: 33652113
doi: 10.1016/j.jconrel.2021.02.031
Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2021;69:166–77.
pubmed: 31715247
doi: 10.1016/j.semcancer.2019.11.002
Zhou M, Yi Y, Liu L, Lin Y, Li J, Ruan J, et al. Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma. J Cancer. 2019;10:5820–31.
pubmed: 31737119
pmcid: 6843872
doi: 10.7150/jca.30865
Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101:59–68.
pubmed: 15588894
doi: 10.1016/j.jconrel.2004.07.003
Talelli M, Barz M, Rijcken CJF, Kiessling F, Hennink WE, Lammers T. Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today. 2015;10:93–117.
pubmed: 25893004
pmcid: 4398985
doi: 10.1016/j.nantod.2015.01.005
Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118:6844–92.
pubmed: 29957926
doi: 10.1021/acs.chemrev.8b00199
Zhang X, Wang D, Han X. Progress of polymeric micelles as drug delivery carriers. Chin J Pharm. 2009;7:177–83.
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103:6315–20.
pubmed: 16606824
pmcid: 1458875
doi: 10.1073/pnas.0601755103
Kalinova R, Dimitrov I. Functional polyion complex micelles for potential targeted hydrophobic drug delivery. Molecules. 2022;27:2178.
pubmed: 35408579
pmcid: 9000450
doi: 10.3390/molecules27072178
Lu Y, Yue Z, Xie J, Wang W, Zhu H, Zhang E, et al. Micelles with ultralow critical micelle concentration as carriers for drug delivery. Nat Biomed Eng. 2018;2:318–25.
pubmed: 30936455
pmcid: 6553490
doi: 10.1038/s41551-018-0234-x
Shi Y, Lammers T, Storm G, Hennink WE. Physico-chemical strategies to enhance stability and drug retention of polymeric micelles for tumor-targeted drug delivery. Macromol Biosci. 2017;17:1600160. https://doi.org/10.1002/mabi.201600160 .
doi: 10.1002/mabi.201600160
Lu Y, Zhang E, Yang J, Cao Z. Strategies to improve micelle stability for drug delivery. Nano Res. 2018;11:4985–98.
pubmed: 30370014
pmcid: 6201237
doi: 10.1007/s12274-018-2152-3
Langridge TD, Gemeinhart RA. Toward understanding polymer micelle stability: density ultracentrifugation offers insight into polymer micelle stability in human fluids. J Control Release. 2019;319:157–67.
pubmed: 31881319
pmcid: 6958513
doi: 10.1016/j.jconrel.2019.12.038
Lu J, Owen SC, Shoichet MS. Stability of self-assembled polymeric micelles in serum. Macromolecules. 2011;44:6002–8.
pubmed: 21818161
pmcid: 3148800
doi: 10.1021/ma200675w
Yin T, Wang P, Li J, Zheng R, Zheng B, Cheng D, et al. Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials. 2013;34:4532–43.
pubmed: 23522375
doi: 10.1016/j.biomaterials.2013.02.067
Yin T, Zheng R, Wang P, Zheng B-W, Ren J, Zhang X. Preparation and in vitro siRNA transfection ability of novel siRNA-Loaded nanobubbles. Chin J Ultrasonogr. 2013;22.
Li S, Yin T, Li J, Zheng B, Qiu C, Wang P. Feasibility of integrating tumor therapy with therapeutic effect evaluation using siRNA-loaded microbubbles. J South Med Univ. 2015;35:874–8.
Wang P, Yin T, Li J, Zheng B, Wang X, Wang Y, et al. Ultrasound-responsive microbubbles for sonography-guided siRNA delivery. Nanomed Nanotechnol Biol Med. 2016;12:1139–49.
doi: 10.1016/j.nano.2015.12.361
Yin T, Wang P, Li J, Wang Y, Zheng B, Zheng R, et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014;35:5932–43.
pubmed: 24746965
doi: 10.1016/j.biomaterials.2014.03.072
Vinchurkar RH, Kuchekar AB. Polymeric micelles: a novel approach towards nano-drug delivery system. Biosci Biotechnol Res Asia. 2021;18:629–49.
Keskin D, Tezcaner A. Micelles as delivery system for cancer treatment. Curr Pharm Des. 2017;23:5230–41.
pubmed: 28552065
Kulthe SS, Choudhari YM, Inamdar NN, Mourya V. Polymeric micelles: authoritative aspects for drug delivery. Des Monomers Polym. 2012;15:465–521.
doi: 10.1080/1385772X.2012.688328
Zhang R, Jiang Y, Hao L, Yang Y, Gao Y, Zhang N, et al. CD44/folate dual targeting receptor reductive response PLGA-based micelles for cancer therapy. Front Pharmacol. 2022;13:829590.
pubmed: 35359873
pmcid: 8960309
doi: 10.3389/fphar.2022.829590
Zhou L, Zhang P, Chen Z, Cai S, Jing T, Fan H, et al. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans. Int J Nanomed. 2017;12:4269–83.
doi: 10.2147/IJN.S124264
Kim G, Piao C, Oh J, Lee M. Self-assembled polymeric micelles for combined delivery of anti-inflammatory gene and drug to the lungs by inhalation. Nanoscale. 2018;10:8503–14.
pubmed: 29693671
doi: 10.1039/C8NR00427G
Hammad RW, Sanad RA-B, Abdelmalak NS, Torad FA, Latif R. New intranasal cross-linked mosapride xyloglucan pluronics micelles (MOS-XPMs) for reflux esophagitis disease: in-vitro optimization and improved therapeutic efficacy. J Adv Res. 2020;23:83–94.
pubmed: 32089877
pmcid: 7025289
doi: 10.1016/j.jare.2020.01.013
Wijiani N, Isadiartuti D, Rijal MAS, Yusuf H. Characterization and dissolution study of micellar curcumin-spray dried powder for oral delivery. Int J Nanomed. 2020;15:1787–96.
doi: 10.2147/IJN.S245050
Yang Y, Tai X, Shi K, Ruan S, Qiu Y, Zhang Z, et al. A new concept of enhancing immuno-chemotherapeutic effects against B16F10 tumor via systemic administration by taking advantages of the limitation of EPR effect. Theranostics. 2016;6:2141–60.
pubmed: 27698946
pmcid: 5039686
doi: 10.7150/thno.16184
Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release. 2013;172:12–21. https://doi.org/10.1016/j.jconrel.2013.06.039 .
doi: 10.1016/j.jconrel.2013.06.039
pubmed: 23920039
Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38.
pubmed: 30009886
pmcid: 6130746
doi: 10.1016/j.addr.2018.07.007
Duan L, Yang L, Jin J, Yang F, Liu D, Hu K, et al. Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications. Theranostics. 2020;10:462–83.
pubmed: 31903132
pmcid: 6929974
doi: 10.7150/thno.37593
Theek B, Baues M, Ojha T, Möckel D, Veettil SK, Steitz J, et al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J Control Release. 2016;231:77–85.
pubmed: 26878973
pmcid: 5404719
doi: 10.1016/j.jconrel.2016.02.021
Meijering BDM, Juffermans LJM, van Wamel A, Henning RH, Zuhorn IS, Emmer M, et al. Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ Res. 2009;104:679–87.
pubmed: 19168443
doi: 10.1161/CIRCRESAHA.108.183806
Hauser J, Ellisman M, Steinau H-U, Stefan E, Dudda M, Hauser M. Ultrasound enhanced endocytotic activity of human fibroblasts. Ultrasound Med Biol. 2009;35:2084–92.
pubmed: 19828232
doi: 10.1016/j.ultrasmedbio.2009.06.1090
Tu J, Yu ACH. Ultrasound-mediated drug delivery: sonoporation mechanisms, biophysics, and critical factors. In: BME Frontiers. Science Partner Journal; 2022. https://spj.sciencemag.org/journals/bmef/2022/9807347/ . Accessed 25 Oct 2022.
Yang Y, Li Q, Guo X, Tu J, Zhang D. Mechanisms underlying sonoporation: interaction between microbubbles and cells. Ultrason Sonochem. 2020;67:105096.
pubmed: 32278246
doi: 10.1016/j.ultsonch.2020.105096
Smith ES, Whitty E, Yoo B, Moore A, Sempere LF, Medarova Z. Clinical applications of short non-coding RNA-based therapies in the era of precision medicine. Cancers (Basel). 2022;14:1588.
pubmed: 35326738
doi: 10.3390/cancers14061588
Kong H, Sun M-L, Zhang X-A, Wang X-Q. Crosstalk among circRNA/lncRNA, miRNA, and mRNA in osteoarthritis. Front Cell Dev Biol. 2021;9:774370.
pubmed: 34977024
pmcid: 8714905
doi: 10.3389/fcell.2021.774370
Godinho BMDC. The era of RNA interference medicines: the clinical landscape of synthetic gene silencing drugs. Saúde & Tecnologia; 2020. p. 5–17.
Ashihara E, Kawata E, Maekawa T. Future prospect of RNA interference for cancer therapies. Curr Drug Targets. 2010;11:345–60.
pubmed: 20210759
doi: 10.2174/138945010790711897
Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.
pubmed: 32088327
doi: 10.1016/j.biotechadv.2020.107534
Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials (Basel). 2020;10:364.
pubmed: 32093140
doi: 10.3390/nano10020364
Ibba ML, Ciccone G, Esposito CL, Catuogno S, Giangrande PH. Advances in mRNA non-viral delivery approaches. Adv Drug Deliv Rev. 2021;177:113930.
pubmed: 34403751
doi: 10.1016/j.addr.2021.113930
Wang Y, Zhang R, Tang L, Yang L. Nonviral delivery systems of mRNA vaccines for cancer gene therapy. Pharmaceutics. 2022;14:512.
pubmed: 35335891
pmcid: 8949480
doi: 10.3390/pharmaceutics14030512
Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–38.
pubmed: 34433919
pmcid: 8386155
doi: 10.1038/s41573-021-00283-5
Xu S, Yang K, Li R, Zhang L. mRNA Vaccine era–mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21:6582.
pubmed: 32916818
pmcid: 7554980
doi: 10.3390/ijms21186582
Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–28.
pubmed: 30846391
pmcid: 6453548
doi: 10.1016/j.ymthe.2019.02.012
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79.
pubmed: 29326426
pmcid: 5906799
doi: 10.1038/nrd.2017.243
Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, et al. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal. 2022;20:26.
pubmed: 35248060
pmcid: 8898478
doi: 10.1186/s12964-021-00796-x
Mahmoud K, Swidan S, El-Nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol. 2022;20:109.
doi: 10.1186/s12951-022-01309-9
Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and cancer: from the development of personalized indicators to novel therapeutic strategies. Front Pharmacol. 2022;13:838079.
pubmed: 35308229
pmcid: 8927697
doi: 10.3389/fphar.2022.838079
Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022;10:3.
pubmed: 35000616
pmcid: 8744248
doi: 10.1186/s40364-021-00350-4
Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med. 2021;11:571–91.
pubmed: 34953051
pmcid: 8817091
doi: 10.1002/cam4.4468
Cheng L, Liu C, Zhang K, Hu Z, Li Y. Construction of pIRES-tPA-DsRed express2-encapsulated PLGA nanoparticles-ultrasound microbubble complexes and study on their cell compatibility. Acta Med Univ Sci Technol Huazhong. 2013;42:377–81.
Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32:3435–46.
pubmed: 21295849
pmcid: 3055170
doi: 10.1016/j.biomaterials.2011.01.021
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–15.
pubmed: 18672949
pmcid: 2663893
doi: 10.1021/mp800051m
He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657–66.
pubmed: 20138662
doi: 10.1016/j.biomaterials.2010.01.065
Sieber S, Grossen P, Uhl P, Detampel P, Mier W, Witzigmann D, et al. Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomed Nanotechnol. 2019;17:82–93.
doi: 10.1016/j.nano.2018.11.017
Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol. 2012;52:481–503.
doi: 10.1146/annurev-pharmtox-010611-134623
Romberg B, Oussoren C, Snel CJ, Hennink WE, Storm G. Effect of liposome characteristics and dose on the pharmacokinetics of liposomes coated with poly(amino acid)s. Pharm Res. 2007;24:2394–401.
pubmed: 17674159
pmcid: 2063565
doi: 10.1007/s11095-007-9393-2
Litzinger DC, Buiting AMJ, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta Biomembranes. 1994;1190:99–107.
doi: 10.1016/0005-2736(94)90038-8
Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14:282–95.
pubmed: 22407288
pmcid: 3326161
doi: 10.1208/s12248-012-9339-4
Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics. 2022;14:106.
pubmed: 35057002
pmcid: 8777701
doi: 10.3390/pharmaceutics14010106
Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther. 2017;42:742–55.
Zhang W, Li C, Jin Y, Liu X, Wang Z, Shaw JP, et al. Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy. Drug Deliv. 2018;25:611–22.
pubmed: 29493300
pmcid: 6058678
doi: 10.1080/10717544.2018.1440669
Hong C, Wang D, Liang J, Guo Y, Zhu Y, Xia J, et al. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer. Theranostics. 2019;9:4437–49.
pubmed: 31285771
pmcid: 6599661
doi: 10.7150/thno.34953
Li Y, Xu P, He D, Xu B, Tu J, Shen Y. Long-circulating thermosensitive liposomes for the targeted drug delivery of oxaliplatin. Int J Nanomed. 2020;15:6721–34.
doi: 10.2147/IJN.S250773
Sebaaly C, Charcosset C, Stainmesse S, Fessi H, Greige-Gerges H. Clove essential oil-in-cyclodextrin-in-liposomes in the aqueous and lyophilized states: from laboratory to large scale using a membrane contactor. Carbohydr Polym. 2016;138:75–85.
pubmed: 26794740
doi: 10.1016/j.carbpol.2015.11.053
Liu T, Zhu W, Han C, Sui X, Liu C, Ma X, et al. Preparation of glycyrrhetinic acid liposomes using lyophilization monophase solution method: preformulation, optimization, and in vitro evaluation. Nanoscale Res Lett. 2018;13:324.
pubmed: 30327946
pmcid: 6191409
doi: 10.1186/s11671-018-2737-5
Lim C, Abuzar SM, Karn PR, Cho W, Park HJ, Cho C-W, et al. Preparation, characterization, and in vivo pharmacokinetic study of the supercritical fluid-processed liposomal amphotericin B. Pharmaceutics. 2019;11:589.
pubmed: 31717352
pmcid: 6921013
doi: 10.3390/pharmaceutics11110589
Lv S, Jing R, Liu X, Shi H, Shi Y, Wang X, et al. One-step microfluidic fabrication of multi-responsive liposomes for targeted delivery of doxorubicin synergism with photothermal effect. Int J Nanomed. 2021;16:7759–72.
doi: 10.2147/IJN.S329621
Khattak MIK, Ahmed N, Umer MF, Riaz A, Ahmad NM, Khan GM. Chloroform-injection (CI) and spontaneous-phase-transition (SPT) are novel methods, simplifying the fabrication of liposomes with versatile solution to cholesterol content and size distribution. Pharmaceutics. 2020;12:1065.
pubmed: 33182248
pmcid: 7695269
doi: 10.3390/pharmaceutics12111065
Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022;14:543.
pubmed: 35335920
pmcid: 8955843
doi: 10.3390/pharmaceutics14030543
Šturm L, Poklar UN. Basic methods for preparation of liposomes and studying their interactions with different compounds, with the emphasis on polyphenols. Int J Mol Sci. 2021;22:6547.
pubmed: 34207189
pmcid: 8234105
doi: 10.3390/ijms22126547
Li Y, Chen Z, Cui Y, Zhai G, Li L. The construction and characterization of hybrid paclitaxel-in-micelle-in-liposome systems for enhanced oral drug delivery. Colloids Surf B. 2017;160:572–80.
doi: 10.1016/j.colsurfb.2017.10.016
Wang S, Gou J, Wang Y, Tan X, Zhao L, Jin X, et al. Synergistic antitumor efficacy mediated by liposomal co-delivery of polymeric micelles of vinorelbine and cisplatin in non-small cell lung cancer. Int J Nanomed. 2021;16:2357–72.
doi: 10.2147/IJN.S290263
Duan H, Liu C, Hou Y, Liu Y, Zhang Z, Zhao H, et al. Sequential delivery of quercetin and paclitaxel for the fibrotic tumor microenvironment remodeling and chemotherapy potentiation via a dual-targeting hybrid micelle-in-liposome system. ACS Appl Mater Interfaces. 2022;14:10102–16.
pubmed: 35175043
doi: 10.1021/acsami.1c23166
Liu Z, Chu W, Sun Q, Zhao L, Tan X, Zhang Y, et al. Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity. Int J Pharm. 2021;602:120619.
pubmed: 33887396
doi: 10.1016/j.ijpharm.2021.120619
Zhang Z, Patel SB, King MR. Micelle-in-liposomes for sustained delivery of anticancer agents that promote potent TRAIL-induced cancer cell apoptosis. Molecules. 2020;26:157.
pubmed: 33396409
pmcid: 7795772
doi: 10.3390/molecules26010157
Xue Y, Feng J, Liu Y, Che J, Bai G, Dong X, et al. A synthetic carrier of nucleic acids structured as a neutral phospholipid envelope tightly assembled on polyplex surface. Adv Healthc Mater. 2020;9:e1901705.
pubmed: 31977157
doi: 10.1002/adhm.201901705
Romana B, Hassan MM, Sonvico F, Garrastazu Pereira G, Mason AF, Thordarson P, et al. A liposome-micelle-hybrid (LMH) oral delivery system for poorly water-soluble drugs: enhancing solubilisation and intestinal transport. Eur J Pharm Biopharm. 2020;154:338–47.
pubmed: 32739535
doi: 10.1016/j.ejpb.2020.07.022
Franzè S, Musazzi UM, Minghetti P, Cilurzo F. Drug-in-micelles-in-liposomes (DiMiL) systems as a novel approach to prevent drug leakage from deformable liposomes. Eur J Pharm Sci. 2019;130:27–35.
pubmed: 30654112
doi: 10.1016/j.ejps.2019.01.013
Xin Y, Qi Q, Mao Z, Zhan X. PLGA nanoparticles introduction into mitoxantrone-loaded ultrasound-responsive liposomes: in vitro and in vivo investigations. Int J Pharm. 2017;528:47–54.
pubmed: 28559216
doi: 10.1016/j.ijpharm.2017.05.059
Oh KS, Lee H, Kim JY, Koo EJ, Lee EH, Park JH, et al. The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy. J Control Release. 2013;165:9–15.
pubmed: 23103984
doi: 10.1016/j.jconrel.2012.10.013
Oh KS, Kim K, Yoon BD, Lee HJ, Park DY, Kim E, et al. Docetaxel-loaded multilayer nanoparticles with nanodroplets for cancer therapy. IJN Dove Press. 2016;11:1077–87.
doi: 10.2147/IJN.S100170
Yuk SH, Oh KS, Koo H, Jeon H, Kim K, Kwon IC. Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs. Biomaterials. 2011;32:7924–31.
pubmed: 21784512
doi: 10.1016/j.biomaterials.2011.07.017
Huo T, Barth RF, Yang W, Nakkula RJ, Koynova R, Tenchov B, et al. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PLoS ONE. 2012;7:e48752.
pubmed: 23152799
pmcid: 3496719
doi: 10.1371/journal.pone.0048752
Sonaje K, Tyagi V, Chen Y, Kalia YN. Iontosomes: electroresponsive liposomes for topical iontophoretic delivery of chemotherapeutics to the buccal mucosa. Pharmaceutics. 2021;13:88.
pubmed: 33440787
pmcid: 7826915
doi: 10.3390/pharmaceutics13010088
Parthenios B. Cancer treatments. 2009.
Boulikas T. Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes. 2003.
Fatima MT, Islam Z, Ahmad E, Barreto GE, Md AG. Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs. Biomed Pharmacother. 2018;107:34–43.
pubmed: 30077836
doi: 10.1016/j.biopha.2018.07.138
Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv. 2011;8:565–80.
pubmed: 21492058
doi: 10.1517/17425247.2011.566552
Hang Z, Cooper MA, Ziora ZM. Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials. Bio Chem Comp. 2016;4:1.
doi: 10.7243/2052-9341-4-2
Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev. 2013;65:1667–85.
pubmed: 24113520
pmcid: 4197009
doi: 10.1016/j.addr.2013.09.014
Zalba S, Garrido MJ. Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv. 2013;10:829–44.
pubmed: 23470129
doi: 10.1517/17425247.2013.778240
Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang VTG. When albumin meets liposomes: a feasible drug carrier for biomedical applications. Pharmaceuticals (Basel). 2021;14:296.
pubmed: 33810483
doi: 10.3390/ph14040296
Zahednezhad F, Zakeri-Milani P, Shahbazi Mojarrad J, Valizadeh H. The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis. Expert Opin Drug Deliv. 2020;17:523–41.
pubmed: 32116060
doi: 10.1080/17425247.2020.1737672
Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep. 2004;12:3–12.
pubmed: 15201951
Stathopoulos GP, Boulikas T. Lipoplatin Formulation Review Article. J Drug Deliv. 2012;2012:581363.
pubmed: 21904682
doi: 10.1155/2012/581363
Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009;18:1197–218.
pubmed: 19604121
doi: 10.1517/13543780903114168
Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomed. 2013;8:3309–19.
Lang T, Liu Y, Zheng Z, Ran W, Zhai Y, Yin Q, et al. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv Mater. 2019;31:e1806202.
pubmed: 30516854
doi: 10.1002/adma.201806202
Wang S, Deng Y, Yan Z, Bi D. Influencing factors in preparation of ciprofloxacin liposomes by ammonium sulfate transmembrane gradients. J Shenyang Pharm Univ. 2003;20:93–6.
Shaker S, Gardouh AR, Ghorab MM. Factors affecting liposomes particle size prepared by ethanol injection method. Res Pharm Sci. 2017;12:346–52.
pubmed: 28974972
pmcid: 5615864
doi: 10.4103/1735-5362.213979
Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758:1633–40.
pubmed: 16887094
doi: 10.1016/j.bbamem.2006.05.028
Fraguas-Sánchez AI, Lozza I, Torres-Suárez AI. Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic. Cancers (Basel). 2022;14:1198.
pubmed: 35267507
doi: 10.3390/cancers14051198
Chen R, Huang L, Hu K. Natural products remodel cancer-associated fibroblasts in desmoplastic tumors. Acta Pharm Sin B. 2020;10:2140–55.
pubmed: 33304782
pmcid: 7714988
doi: 10.1016/j.apsb.2020.04.005
Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16–27.
pubmed: 24956577
doi: 10.1016/j.semcancer.2014.06.004
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Maione P, Rossi A, Bareschino MA, Sacco PC, Schettino C, Falanga M, et al. Factors driving the choice of the best second-line treatment of advanced NSCLC. Rev Recent Clin Trials. 2011;6:44–51.
pubmed: 20868346
doi: 10.2174/157488711793980192
Ni M, Wang H, Wang M, Zhou W, Zhang J, Wu J, et al. Investigation on the efficiency of Chinese herbal injections for treating non-small cell lung cancer with vinorelbine and cisplatin based on multidimensional bayesian network meta-analysis. Front Pharmacol. 2021;11:631170.
pubmed: 33708126
pmcid: 7941272
doi: 10.3389/fphar.2020.631170
Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
pubmed: 31003078
doi: 10.1016/j.bioorg.2019.102925
Lu X, Zhang F, Qin L, Xiao F, Liang W. Polymeric micelles as a drug delivery system enhance cytotoxicity of vinorelbine through more intercellular accumulation. Drug Deliv. 2010;17:255–62.
pubmed: 20307251
doi: 10.3109/10717541003702769
McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res. 2010;71:799–808.
pubmed: 20594083
doi: 10.2460/ajvr.71.7.799
van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer. 1999;35:808–14.
pubmed: 10505043
doi: 10.1016/S0959-8049(99)00004-0
van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer. 1999;80:981–90.
pubmed: 10362105
pmcid: 2363050
doi: 10.1038/sj.bjc.6690452
Poon C, Duan X, Chan C, Han W, Lin W. Nanoscale coordination polymers codeliver carboplatin and gemcitabine for highly effective treatment of platinum-resistant ovarian cancer. Mol Pharm. 2016;13:3665–75.
pubmed: 27712076
pmcid: 5673481
doi: 10.1021/acs.molpharmaceut.6b00466
Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411.
pubmed: 33679401
pmcid: 7933596
doi: 10.3389/fphar.2021.618411
Ahadian S, Finbloom JA, Mofidfar M, Diltemiz SE, Nasrollahi F, Davoodi E, et al. Micro and nanoscale technologies in oral drug delivery. Adv Drug Deliv Rev. 2020;157:37–62.
pubmed: 32707147
pmcid: 7374157
doi: 10.1016/j.addr.2020.07.012
Reinholz J, Landfester K, Mailänder V. The challenges of oral drug delivery via nanocarriers. Drug Deliv. 2018;25:1694–705.
pubmed: 30394120
pmcid: 6225504
doi: 10.1080/10717544.2018.1501119
Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: a review. Biomater Res. 2021;25:24.
pubmed: 34321111
pmcid: 8317283
doi: 10.1186/s40824-021-00226-6
Yu Y-Q, Yang X, Wu X-F, Fan Y-B. Enhancing permeation of drug molecules across the skin via delivery in nanocarriers: novel strategies for effective transdermal applications. Front Bioeng Biotechnol. 2021;9:646554.
pubmed: 33855015
pmcid: 8039394
doi: 10.3389/fbioe.2021.646554
Uchida N, Yanagi M, Hamada H. Physical enhancement? Nanocarrier? Current progress in transdermal drug delivery. Nanomaterials (Basel). 2021;11:335.
pubmed: 33525364
doi: 10.3390/nano11020335
Franzé S, Donadoni G, Podestà A, Procacci P, Orioli M, Carini M, et al. Tuning the extent and depth of penetration of flexible liposomes in human skin. Mol Pharm. 2017;14:1998–2009.
pubmed: 28409629
doi: 10.1021/acs.molpharmaceut.7b00099
Franzé S, Marengo A, Stella B, Minghetti P, Arpicco S, Cilurzo F. Hyaluronan-decorated liposomes as drug delivery systems for cutaneous administration. Int J Pharm. 2018;535:333–9.
pubmed: 29146539
doi: 10.1016/j.ijpharm.2017.11.028
Zhang W, Wang G, Falconer JR, Baguley BC, Shaw JP, Liu J, et al. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharm Res. 2015;32:1451–61.
pubmed: 25355460
doi: 10.1007/s11095-014-1551-8
See E, Zhang W, Liu J, Svirskis D, Baguley BC, Shaw JP, et al. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. Int J Pharm. 2014;473:528–35.
pubmed: 25079434
doi: 10.1016/j.ijpharm.2014.07.033
Andra VVSNL, Pammi SVN, Bhatraju LVKP, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience. 2022;12:274–91.
pubmed: 35096502
pmcid: 8790012
doi: 10.1007/s12668-022-00941-x
Maja L, Željko K, Mateja P. Sustainable technologies for liposome preparation. J Supercrit Fluids. 2020;165:104984.
doi: 10.1016/j.supflu.2020.104984
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37.
pubmed: 27834398
doi: 10.1038/nrc.2016.108